

09/446601

Client Identifier: SANOFISYNTHELABO/RESEARCH/428 Rec'd PCT/PTO 22 DEC 1999
Date of Request: 12/17/99
The Current Database is WPI
Your Terms and Connectors Query:

PN("WO 9717064!")

(c) 1999 Derwent Info Ltd. All rights reserved.

199725

Stabilised lyophilised composition existing as mixture of amorphous and crystalline phases - contains non-protein pharmaceutical and synergistic combination of mannitol and alanine as stabiliser, providing stability for drug in aqueous solution

Patent Assignee: SANOFI SA (SNFI)

Inventor: BOULOUMIE C; BREUL T; COLLIERE L; FAURE P; BOULOMIE C

Number of Countries: 076

Number of Patents: 013

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9717064	A1	19970515	WO 96FR1706	A	19961030	A61K-009/19	199725 B
FR 2740686	A1	19970509	FR 9513022	A	19951103	A61K-047/42	199726
AU 9674990	A	19970529	AU 9674990	A	19961030	A61K-009/19	199737
ZA 9609176	A	19980624	ZA 969176	A	19961031	A61K-000/00	199831
CZ 9801231	A3	19980715	WO 96FR1706	A	19961030	A61K-009/19	199835
CZ 981231	A	19961030					
NO 9801967	A	19980630	WO 96FR1706	A	19961030	A61K-009/14	199836
NO 981967	A	19980430					
EP 858325	A1	19980819	EP 96937367	A	19961030	A61K-009/19	199837
WO 96FR1706	A	19961030					
SK 9800525	A3	19981007	WO 96FR1706	A	19961030	A61K-009/19	199850
SK 98525	A	19961030					
BR 9611367	A	19990223	BR 9611367	A	19961030	A61K-009/19	199913
WO 96FR1706	A	19961030					
CN 1203527	A	19981230	CN 96198786	A	19961030	A61K-009/19	199920
NZ 321616	A	19990429	NZ 321616	A	19960930	A61K-009/19	199923
HU 9900016	A2	19990628	WO 96FR1706	A	19961030	A61K-009/19	199931
HU 9916	A	19961030					
JP 11507945	W	19990713	WO 96FR1706	A	19961030	A61K-009/19	199938
JP 97517912	A	19961030					

Priority Applications (No Type Date): FR 9513022 A 19951103

Cited Patents: Jnl.Ref; EP 394045; EP 682944; GB 2021581; JP 2096536; JP 50088215; US 4537883; WO 9323017

Patent Details:

Patent Kind Lan Pg Filing Notes Application Patent

WO 9717064 A1 F 43

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU
CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG
US

UZ VN

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GR IE IT KE
LS LU MC MW NL OA PT SD SE SZ UG

FR 2740686 A1 31

AU 9674990 A Based on WO 9717064

ZA 9609176 A 43

CZ 9801231 A3 Based on WO 9717064

EP 858325 A1 F Based on WO 9717064

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LT

LU LV MC NL PT SE SI

BR 9611367 A Based on WO 9717064

HU 9900016 A2 Based on WO 9717064

JP 11507945 W 44 Based on WO 9717064

Abstract (Basic): WO 9717064 A

Lyophilised pharmaceutical formulation (A) consisting of amorphous
and crystalline phases, comprises: (i) a non-protein active ingredient
(I); (ii) mannitol (II); and (iii) alanine (III). The weight ratio of
(II) : (III) is 0.1-1.

USE - The composition is particularly useful for (I) which are not
very stable in aqueous solution. (A) can be administered orally,
directly, or orally or parenterally after reconstitution with water.

ADVANTAGE - (A) can be stored at 25-40 deg. C without loss of
chemical or biological stability and can be reconstituted by addition
of solvent. (II) and (III) have a synergistic stabilising action when
used at the specified ratio; this is attributed to existence of the
two-phase system.

Dwg.0/2

Title Terms: STABILISED; LYOPHILISE; COMPOSITION; EXIST; MIXTURE;
AMORPHOUS

; CRYSTAL; PHASE; CONTAIN; NON; PROTEIN; PHARMACEUTICAL; SYNERGISTIC;
COMBINATION; MANNITOL; ALANINE; STABILISED; STABILISED; DRUG;
AQUEOUS;
SOLUTION

Derwent Class: B05; B07

International Patent Class (Main): A61K-000/00; A61K-009/14; A61K-009/19;
A61K-047/42

International Patent Class (Additional): A61K-031/41; A61K-031/425;
A61K-047/18; A61K-047/26; A61K-047/42; A61K-047-10

File Segment: CPI

Manual Codes (CPI/A-N): B06-D01; B07-H; B10-A07; B10-B02J; B12-M06; B14-S09

END OF DOCUMENT